These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37846412)

  • 1. Extraordinarily high serum CA 19-9 in setting of pancreatic necrosis and underlying pancreatic adenocarcinoma: a case report.
    McConnell A; Stoneman T; Hewlett S
    J Surg Case Rep; 2023 Oct; 2023(10):rjad550. PubMed ID: 37846412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case of Choledocholithiasis and Obstructive Jaundice With a Very High Serum Carbohydrate Antigen 19-9 (CA 19-9) Level: A Case Report and Review of Literature.
    Ghallab M; Abosheaishaa H; Gupta I; Abdelmoteleb S; Stern R
    Cureus; 2022 Dec; 14(12):e32447. PubMed ID: 36644102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
    Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
    PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.
    Ballehaninna UK; Chamberlain RS
    J Gastrointest Oncol; 2012 Jun; 3(2):105-19. PubMed ID: 22811878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.
    Ballehaninna UK; Chamberlain RS
    Indian J Surg Oncol; 2011 Jun; 2(2):88-100. PubMed ID: 22693400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune Pancreatitis Masquerading as Pancreatic Cancer: A Case Report and Literature Review.
    Agarwal KK; Jassal R; Browne A; Hossain M; Akhtar R
    Cureus; 2022 Feb; 14(2):e21900. PubMed ID: 35265424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neopterin serum levels in pancreatic adenocarcinoma.
    Manes G; Spada OA; Rabitti PG; Feola B; Misso S; Minerva A; Uomo G
    Int J Pancreatol; 1999 Feb; 25(1):31-7. PubMed ID: 10211419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice.
    Duraker N; Hot S; Polat Y; Höbek A; Gençler N; Urhan N
    J Surg Oncol; 2007 Feb; 95(2):142-7. PubMed ID: 17262731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
    Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
    Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.
    Koopmann J; Buckhaults P; Brown DA; Zahurak ML; Sato N; Fukushima N; Sokoll LJ; Chan DW; Yeo CJ; Hruban RH; Breit SN; Kinzler KW; Vogelstein B; Goggins M
    Clin Cancer Res; 2004 Apr; 10(7):2386-92. PubMed ID: 15073115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is CA242 really a new tumour marker for pancreatic adenocarcinoma?
    Plebani M; Basso D; Navaglia F; D'Angeli F; Panozzo MP; Del Giudice G; Battistel M; Meggiato T; Del Favero G
    Oncology; 1995; 52(1):19-23. PubMed ID: 7800337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.
    Malesci A; Tommasini MA; Bonato C; Bocchia P; Bersani M; Zerbi A; Beretta E; Di Carlo V
    Gastroenterology; 1987 Jan; 92(1):60-7. PubMed ID: 3465666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
    Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS
    Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.
    Haglund C; Kuusela P; Jalanko H; Roberts PJ
    Int J Cancer; 1987 Apr; 39(4):477-81. PubMed ID: 3470260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA 19-9: Biochemical and Clinical Aspects.
    Scarà S; Bottoni P; Scatena R
    Adv Exp Med Biol; 2015; 867():247-60. PubMed ID: 26530370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.
    Kim MS; Jeon TJ; Park JY; Choi J; Shin WC; Park SE; Seo JY; Kim YM
    Korean J Gastroenterol; 2017 Aug; 70(2):96-102. PubMed ID: 28830135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extraordinarily elevated serum levels of CA 19-9 and rapid decrease after successful therapy: a case report and review of literature.
    Korkmaz M; Ünal H; Selçuk H; Yilmaz U
    Turk J Gastroenterol; 2010 Dec; 21(4):461-3. PubMed ID: 21332006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.